BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25874774)

  • 1. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort.
    Mihelich BL; Maranville JC; Nolley R; Peehl DM; Nonn L
    PLoS One; 2015; 10(4):e0124245. PubMed ID: 25874774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
    Jin W; Fei X; Wang X; Chen F; Song Y
    J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
    Zedan AH; Blavnsfeldt SG; Hansen TF; Nielsen BS; Marcussen N; Pleckaitis M; Osther PJS; Sørensen FB
    PLoS One; 2017; 12(6):e0179113. PubMed ID: 28628624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.
    Zedan AH; Hansen TF; Assenholt J; Madsen JS; Osther PJS
    Prostate; 2019 Mar; 79(4):425-432. PubMed ID: 30537232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
    Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
    Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
    Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of urine-circulating miRNAs for detection of prostate cancer.
    Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
    Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
    Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
    Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
    Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
    PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
    Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
    Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
    Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
    Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.